Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism: a Phase 0 Trial

Next Previous
X
Search
Trial Profile

ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism: a Phase 0 Trial

Status: Completed
Phase of Trial: Phase 0

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; ME 344 (Primary)
  • Indications Early breast cancer; HER2 negative breast cancer
  • Focus Pharmacodynamics; Therapeutic Use

    • Most Recent Events

    • 09 Oct 2019 Results published in the Clinical Cancer Research
    • 04 Jun 2019 Primary endpoint (Ki67% relative reduction from d0 to 28) has been met, according to the results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
    • 04 Jun 2019 Results assessing the activity of the combination in patients showing vascular normalization according to FDG-PET, presented at the 55th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top